Sigyn Therapeutics, Inc. (SIGY) stock
SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $48.16KP/E –Yield –
Sigyn Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Sigyn Therapeutics's operating income for the twelve months ending Sep 30, 2025 was -$1.88M. For fiscal 2024 it was -$2.52M. The highest annual figure on record is -$387.54K in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$2.52M | – |
| FY2023 | Dec 31, 2023 | -$2.46M | – |
| FY2022 | Dec 31, 2022 | -$2.15M | – |
| FY2021 | Dec 31, 2021 | -$2.01M | – |
| FY2020 | Dec 31, 2020 | -$916.43K | – |
| FY2019 | Dec 31, 2019 | -$517.96K | – |
| FY2018 | Dec 31, 2018 | -$1.00M | – |
| FY2017 | Dec 31, 2017 | -$2.03M | – |
| FY2015 | Dec 31, 2015 | -$2.25M | – |
| FY2014 | Dec 31, 2014 | -$387.54K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -$386.53K | – |
| Q2 FY2025 | Jun 30, 2025 | -$469.51K | – |
| Q1 FY2025 | Mar 31, 2025 | -$546.06K | – |
| Q4 FY2024 | Dec 31, 2024 | -$478.01K | – |
| Q3 FY2024 | Sep 30, 2024 | -$808.46K | – |
| Q2 FY2024 | Jun 30, 2024 | -$602.81K | – |
| Q1 FY2024 | Mar 31, 2024 | -$629.97K | – |
| Q4 FY2023 | Dec 31, 2023 | -$717.24K | – |
| Q3 FY2023 | Sep 30, 2023 | -$642.81K | – |
| Q2 FY2023 | Jun 30, 2023 | -$574.01K | – |
| Q1 FY2023 | Mar 31, 2023 | -$521.26K | – |
| Q4 FY2022 | Dec 31, 2022 | -$471.59K | – |
| Q3 FY2022 | Sep 30, 2022 | -$533.65K | – |
| Q2 FY2022 | Jun 30, 2022 | -$532.80K | – |
| Q1 FY2022 | Mar 31, 2022 | -$609.24K | – |
| Q4 FY2021 | Dec 31, 2021 | -$590.94K | – |
| Q3 FY2021 | Sep 30, 2021 | -$573.36K | – |
| Q2 FY2021 | Jun 30, 2021 | -$441.82K | – |
| Q1 FY2021 | Mar 31, 2021 | -$402.10K | – |
| Q4 FY2020 | Dec 31, 2020 | -$344.57K | – |
| Q3 FY2020 | Sep 30, 2020 | -$202.98K | – |
| Q2 FY2020 | Jun 30, 2020 | -$175.91K | – |
| Q1 FY2020 | Mar 31, 2020 | -$192.98K | – |
| Q4 FY2019 | Dec 31, 2019 | -$125.06K | – |
| Q3 FY2019 | Sep 30, 2019 | -$122.73K | – |
| Q2 FY2019 | Jun 30, 2019 | -$101.32K | – |
| Q1 FY2019 | Mar 31, 2019 | -$168.86K | – |
| Q4 FY2018 | Dec 31, 2018 | -$241.48K | – |
| Q3 FY2018 | Sep 30, 2018 | -$241.30K | – |
| Q2 FY2018 | Jun 30, 2018 | -$233.09K | – |
| Q1 FY2018 | Mar 31, 2018 | -$288.24K | – |
| Q4 FY2017 | Dec 31, 2017 | -$491.67K | – |
| Q3 FY2017 | Sep 30, 2017 | -$580.21K | – |
| Q2 FY2017 | Jun 30, 2017 | -$615.33K | – |
| Q1 FY2017 | Mar 31, 2017 | -$344.17K | – |
| Q3 FY2016 | Sep 30, 2016 | -$329.44K | – |
| Q2 FY2016 | Jun 30, 2016 | -$526.88K | – |
| Q1 FY2016 | Mar 31, 2016 | -$712.68K | – |
| Q4 FY2015 | Dec 31, 2015 | -$811.96K | – |
See a number that looks wrong?